Exhibit 99.1
Actavis Pharma Segment Revenue
(Unaudited; $ in millions) | Three Months Ended March 31, 2014 | Twelve Months Ended December 31, 2013 | Three Months Ended December 31, 2013 | Three Months Ended September 30, 2013 | Three Months Ended June 30, 2013 | Three Months Ended March 31, 2013 | Twelve Months Ended December 31, 2012 | Twelve Months Ended December 31, 2011 | ||||||||||||||||||||||||
North American Brands: | ||||||||||||||||||||||||||||||||
Women’s Health | $ | 212.6 | $ | 292.8 | $ | 224.6 | $ | 26.9 | $ | 21.3 | $ | 20.0 | $ | 61.9 | $ | 32.5 | ||||||||||||||||
Urology / Gastroenterology | 225.2 | 408.8 | 236.1 | 60.2 | 55.8 | 56.7 | 217.7 | 209.0 | ||||||||||||||||||||||||
Dermatology / Established Brands | 156.2 | 360.9 | 174.4 | 65.9 | 67.7 | 52.9 | 198.6 | 190.6 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
Total North American Brands | 594.0 | 1,062.5 | 635.1 | 153.0 | 144.8 | 129.6 | 478.2 | 432.1 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
North American Generics | 1,024.2 | 3,915.7 | 1,033.1 | 976.1 | 949.8 | 956.7 | 3,472.2 | 2,945.6 | ||||||||||||||||||||||||
International | 646.7 | 2,502.5 | 728.1 | 576.8 | 619.4 | 578.2 | 978.1 | 430.5 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
Net Revenues | $ | 2,264.9 | $ | 7,480.7 | $ | 2,396.3 | $ | 1,705.9 | $ | 1,714.0 | $ | 1,664.5 | $ | 4,928.5 | $ | 3,808.2 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our North American Brands Revenue consists of three categories: Women’s Healh, Urology/Gastroenterology, and Dermatology/Established Brands. The products that make up each category are as follows:
Women’s Health | Urology/Gastroenterology | Dermatology/Established Brands | ||||
Atelvia® | Androderm® | Cordran® Tape | Tri-Norinyl® | |||
Crinone® | Asacol® | Doryx® | Oxytrol® | |||
Estrace® Cream | Asacol® HD/Asacol® 800 | Actonel® | Gelnique® | |||
Generess® Fe | Delzicol® | Actonel DR® | Sodium Ferric Gluconate | |||
Lo Loestrin® Fe | Enablex® | INFeD® | Actigall® | |||
Loestrin® 24 Fe | Rapaflo® | Kadian® | Condylox® | |||
Minastrin® 24 Fe | Trelstar® | Alora® | Fioricet® | |||
Fibristal™ | AndroGel® Copromotion Revenue | Brevicon® | Fiorinal® | |||
ella® | Norco® | |||||
Estrace® Tablets | Microzide® | |||||
Femring® | Femcon® Fe | |||||
Norinyl® | femhrt® | |||||
Nor-QD® | Sarafem® | |||||
PapSure® | Estrostep® Fe | |||||
PreQue 10™ | Ovcon® | |||||
Royalty, Supply & Other Revenue |